Effects of ethinyl estradiol on semen quality and various hormonal parameters in a eugonadal male

Lübbert, H.; Leo-Rossberg, I; Hammerstein, J.

doi:10.1016/s0015-0282(16)55271-6

Cited by 70 publications

(24 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prolonged exposure to oestrogens has been associated with decreased spermatogenesis and azoospermia due to gonadotropin suppression, but whether long‐term testicular damage occurs is unclear. Currently, there are no data in the literature regarding the recovery of spermatogenesis and fertility after discontinuation of CHT .…”

Section: Reproductive Functionmentioning

confidence: 99%

Endocrine care of transpeople part II. A review of cross‐sex hormonal treatments, outcomes and adverse effects in transwomen

Meriggiola

Gava

2015

Clinical Endocrinology

View full text Add to dashboard Cite

The treatment of transwomen relies on the combined administration of anti-androgens or GnRH analogues to suppress androgen production and thereby reduce male phenotypic characteristics together with oestrogens to develop female characteristics. In transwomen, synthetic oestrogens such as ethinyl oestradiol, as well as conjugated equine oestrogens (CEE), should be avoided to minimize thromboembolic risks especially in older transwomen and in those with risk factors. Currently, available short- and long-term safety studies suggest that cross-sex hormonal therapy (CHT) can be considered safe in transwomen improving the well-being and quality of life of these individuals. Long-term monitoring should aim to decrease cardiovascular risks and should include prostate and breast cancer screenings.

show abstract

Section: Reproductive Functionmentioning

confidence: 99%

Endocrine care of transpeople part II. A review of cross‐sex hormonal treatments, outcomes and adverse effects in transwomen

Meriggiola

Gava

2015

Clinical Endocrinology

View full text Add to dashboard Cite

show abstract

“…There are no prospective clinical studies of fertility among patients undergoing feminizing hormone therapy. Two small studies of MtF patients on feminizing hormone therapy demonstrate changes in the testes consistent with hypospermatogenesis and decreased sperm motility (Lubbert, Leo-Rossberg, & Hammerstein, 1992;Schulze, 1988), suggesting a significant impairment in fertility.…”

Section: Side Effects Of Feminizing Therapymentioning

confidence: 99%

Hormone Therapy in Adults: Suggested Revisions to the Sixth Version of theStandards of Care

Feldman

Safer

2009

International Journal of Transgenderism

View full text Add to dashboard Cite

Often viewed as the definitive professional document on transgender care, the current Standards of Care for Gender Identity Disorders-Sixth Version provides a general overview of the risks and effects of adult hormone therapy, but at present offers limited guidance for the medical provider as to how best to execute this critical intervention. Newer versions need to present a comprehensive approach to transgender hormone therapy, including preventive health care, by incorporating the following key elements: the prescribing physician's responsibilities, clinical situations for hormone therapy, effects and risks of hormone therapy, assessment for initiating hormone therapy, monitoring hormone therapy, and suggested hormone regimens.

show abstract

“…In addition, estradiol-17fl has been reported to stimulate the production of CRF by the isolated hypothalamus in vitro [11] and also to increase serum pregnenolone, cortisol and dehydroepiandrosterone sulfate (DHEA-S) in postmenopausal women [12]. On the other hand, estrogen has been reported to eliminate serum DHEA-S in men [13]. Estrogens inhibit porcine testicular microsomal cytochrome P-450 (17a-hydroxylase/C-17,20-lyase) in vitro [14] A: Suppression of serum FSH by DES-DP administration in patients (n=4) treated with LHRH-A.…”

Section: Discussionmentioning

confidence: 99%

Stronger Suppression of Serum Testosterone and FSH Levels by a Synthetic Estrogen than by Castration or an LH-RH Agonist.

et al. 1997

View full text Add to dashboard Cite

Abstract. Serum levels of LH, FSH and testosterone (T) were measured by radioimmunoassays in 36 patients with advanced prostate cancer before and during androgen ablation therapies. Both leuprolide acetate (LH-RH agonist: LHRH-A) and diethylstilbestrol diphosphate (DES-DP) administration decreased serum LH significantly to an undetectable level (LHRH-A: P<0.01, DES-DP: P<0.05). LHRH-A and DES-DP diminished serum FSH to 20% of the pre-treatment level (P<0.005) and to an undetectable level (P<0.001), respectively.LHRH-A and DES-DP decreased serum T to the castration level and an undetectable level, respectively (P<0.001). Serum levels of the same 3 hormones before and after DES-DP administration were measured in 8 patients who received DES-DP after LHRH-A treatment or castration because of relapse of the disease. DES-DP lowered serum FSH further than LHRH-A to an undetectable level (P<0.005) and diminished T further than previous treatments to an undetectable level (P<0.05 vs. LHRH-A, P<0.01 vs. castration). These results suggest that 1) DES-DP is able to reduce T production from extra-testicular site(s), and achieve the minimal serum T level, and 2) this DES-DP action appears to be one off the mechanisms of the effectiveness of estrogen on refractory prostate cancer after castration or LHRH-A. In addition, basal (independent of LH-RH) FSH secretion in elderly men is about 20% of total FSH secretion and DES-DP inhibits the basal FSH secretion at the level of the pituitary.

show abstract

Effects of ethinyl estradiol on semen quality and various hormonal parameters in a eugonadal male

Cited by 70 publications

References 16 publications

Endocrine care of transpeople part II. A review of cross‐sex hormonal treatments, outcomes and adverse effects in transwomen

Endocrine care of transpeople part II. A review of cross‐sex hormonal treatments, outcomes and adverse effects in transwomen

Hormone Therapy in Adults: Suggested Revisions to the Sixth Version of theStandards of Care

Stronger Suppression of Serum Testosterone and FSH Levels by a Synthetic Estrogen than by Castration or an LH-RH Agonist.

Contact Info

Product

Resources

About